Facile Therapeutics is bringing Ebselen into the clinic to demonstrate it will be effective in preventing the recurrence of CDI in a Proof-of-Concept (PoC) clinical trial.

Biotechnology

Facile Therapeutics

Marc Navre

Allan Wagman

The executive team at Facile Therapeutics has a history of working in the biotech industry and holding positions in drug discovery and development. They have experience with companies such as Basecamp Bio, Wemberly Scientific, Inc., Ardelyx, and Catalyst Biosciences.

CEO and Executive Team

About

Team members

Other teams at Facile Therapeutics

Board of Directors

Leadership Team

Founding Team